Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock
NASDAQ · AUPH
16.48
Fundamentals
Market cap
$2.19B
Price / Earnings ratio
7.0x
Price / Sales ratio
7.1x
Price / Book ratio
3.6x
Return on assets
48.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
NeutralAUPHAugust 20, 2026
Zacks Investment ResearchNeutral
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH

Stocktwits
AUPH Stock Rallies 6% After-Hours — Here’s Why
NeutralAUPHAugust 19, 2026
StocktwitsNeutral
AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH

Business Wire
Aurinia Settles Patent Litigation with Teva
NeutralAUPHAugust 19, 2026
Business WireNeutral
Aurinia Settles Patent Litigation with Teva
AUPH

Zacks Investment Research
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
NeutralAUPHAugust 6, 2026
Zacks Investment ResearchNeutral
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
AUPH
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
345M227M114M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
902M595M298M0
Revenue to Profit
2025$283.1M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$287.2M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
NeutralAUPHAugust 20, 2026
Zacks Investment ResearchNeutral
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH

Stocktwits
AUPH Stock Rallies 6% After-Hours — Here’s Why
NeutralAUPHAugust 19, 2026
StocktwitsNeutral
AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH

Business Wire
Aurinia Settles Patent Litigation with Teva
NeutralAUPHAugust 19, 2026
Business WireNeutral
Aurinia Settles Patent Litigation with Teva
AUPH

Zacks Investment Research
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
NeutralAUPHAugust 6, 2026
Zacks Investment ResearchNeutral
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
AUPH

Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
NeutralAUPHAugust 6, 2026
Business WireNeutral
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
AUPH

Business Wire
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
NeutralAUPHJuly 6, 2026
Business WireNeutral
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
AUPH

Zacks Investment Research
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
NeutralAUPHJuly 2, 2026
Zacks Investment ResearchNeutral
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
AUPH

Zacks Investment Research
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
NeutralAUPHJune 26, 2026
Zacks Investment ResearchNeutral
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
AUPH

Zacks Investment Research
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
NeutralAUPHJune 25, 2026
Zacks Investment ResearchNeutral
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
AUPH

Zacks Investment Research
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
NeutralAUPHJune 23, 2026
Zacks Investment ResearchNeutral
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
AUPH
About Aurinia Pharmaceuticals Inc Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees128
CEOMr. Kevin C. Tang
IPO DateJan 26, 1999
HeadquartersEdmonton, AB
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin C. Tang | Chairman & CEO | 1967 |
| Mr. Stephen P. Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 1982 |
| Mr. Peter S. Greenleaf M.B.A. | Consultant | 1970 |
| Mr. Michael S. Hearne CPA | Chief Financial Officer | 1963 |
| Mr. Ryan Cole | Chief Operating Officer | 1987 |
| Mr. Thomas Wei | Chief Scientific Officer | 1976 |
| Mr. Stewart M. Kroll | Chief Development Officer | 1959 |
Fundamentals
Valuation
Market cap$2.19B
Price-to-sales ratio7.09
Price-to-book value3.59
Price-earnings ratio7.00
Return on Equity65.00%
Return on Sales46.00%
Return on Assets48.00%
PEG ratio0.00
Earnings Per Share
Earnings Per Share$2.36
Income Statement
Average volume816,576
EBITDA$157.42M
1 year high (52w)$19.25
1 year low (52w)$10.34
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
1 Wall Street Analyst Ratings
HOLD
0% Buy
100% Hold
0% Sell
Target price
$16.00
Est return
3.38%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.7 | +51.7 | -42.3 | +28.6 | ||||||||
| 2022 | -25.9 | -30.3 | +3.1 | -18.3 | +3.6 | -9.3 | -28.2 | -9.6 | +3.2 | +9.9 | -36.0 | -14.8 |
| 2023 | +52.4 | -1.9 | +21.9 | +9.0 | -20.0 | +6.1 | +15.9 | -13.2 | -17.9 | -1.3 | +21.2 | -0.8 |
| 2024 | -13.7 | -26.0 | -13.3 | -5.7 | +4.2 | +6.5 | +7.1 | +21.4 | +9.7 | -0.7 | +21.0 | -1.3 |
| 2025 | -9.4 | +1.8 | +0.8 | +2.4 | -4.4 | +6.4 | +23.7 | +14.3 | -5.4 | +15.5 | +22.4 | -1.4 |
| 2026 | -5.3 | -6.9 | +4.3 | -0.5 | -0.1 | +10.8 | -5.8 | +10.6 | +2.4 |



